

# Pulmonary Rehabilitation Part Two

Arthur Jones, EdD, RRT

<http://rc-edconsultant.com/>

## Learning Objectives:

- ▲ Integrate pharmacological agents into pulmonary rehabilitation (PR).
- ▲ Integrate oxygen therapy into a PR program.
- ▲ Integrate ventilatory muscle training for PR patients.
- ▲ Integrate general exercise training for PR patients.
- ▲ Describe PR for patients with conditions other than obstructive disease.
- ▲ Assess outcomes for PR patients.
- ▲ Explain the implications of special issues associated with PR; such as, patient adherence, ethical issues and social support.

## Rehabilitation Interventions Overview

## Interventions (RC):

- ▲ Education on RC topics
- ▲ Dyspnea management
- ▲ Pharmacotherapy
- ▲ Oxygen therapy
- ▲ Inspiratory muscle training
- ▲ Exercise training
- ▲ Smoking cessation
- ▲ Sleep assessment and therapy

FYI - Click for AARC CPG Pulmonary Rehabilitation  
<http://www.rcjournal.com/cpgs/pdf/05.02.616.pdf>

## Interventions (non-RC):

- ▲ Occupational therapy
- ▲ Physical therapy
- ▲ Nutritional support
- ▲ Psychosocial support, including end-of-life care
- ▲ Alternative medical support

## Initiation of rehabilitation

- ▲ After first exacerbation
- ▲ During intensive care
- ▲ Before and after surgical procedures; e.g., lung volume reduction surgery (LVRS)
- ▲ When the patient is ready

**Duration of rehabilitation**

^6-12 weeks

**Pharmacologica  
I  
Therapy**

**Components of COPD**

- ^ Airflow obstruction - decreased FEV<sub>1</sub>
- ^ Hyperinflation - increased IC/TLC
- ^ Inflammation
- ^ Systemic manifestations, due to oxidative stress, immunopathology result in:
  - ◆ decreased free fat mass;
  - ◆ impaired muscle function;
  - ◆ dyspnea; etc.

**Medication types for COPD**

- ^ Immunizations: influenza; pneumococcus
- ^ Bronchodilators
- ^ Corticosteroids
- ^ Combination therapy
- ^ Mucolytics
- ^ Antibiotics

**Bronchodilators**

- ^ Benefits
  - ◆ decrease airway resistance
  - ◆ decrease hyperinflation
  - ◆ decrease dyspnea - may be due to decreased resistance and/or decreased hyperinflation
  - ◆ note - patients may improve symptoms, although FEV<sub>1</sub> remains unchanged.

**Bronchodilators**

- ^ Short-acting beta-agonist (SABA)
  - ◆ albuterol, as needed
  - ◆ all stages

**Bronchodilators**

- ^ Long-acting beta-agonists (LABA)-  
moderate-to-severe COPD
  - ◆ salmeterol (Serevent)
  - ◆ formoterol (Foradil)
  - ◆ indacaterol (Arcapta Neohaler)
    - ▶ once daily
    - ▶ FDA approved in July, 2011
    - ▶ better than tiotropium for COPD??

**Bronchodilators**

- ^ Short-acting anticholinergic -  
ipratropium (Atrovent)
- ^ Long-acting anticholinergic -  
tiotropium (Spiriva)
  - ◆ moderate-to-severe
  - ◆ improves lung function
  - ◆ decreases dyspnea
  - ◆ daily - increases adherence

**Bronchodilators**

- ^ nonspecific phosphodiesterase  
(PDE) inhibitors; e.g., theophylline
  - ◆ high risk/benefit ratio - adverse  
effects
  - ◆ low cost
  - ◆ reserved for patients who cannot use  
aerosols

**Bronchodilators**

- ^ PDE4 inhibitors; e.g., roflumilast  
(Daliresp)
  - ◆ included in Global Initiative for  
Chronic Obstructive Lung Disease  
(GOLD) guidelines for severe COPD
  - ◆ daily tablet
  - ◆ bronchodilator
  - ◆ decreases inflammation
  - ◆ decreases exacerbations

Click for information on PDE4 inhibition

<http://www.thinkcopdifferently.com/Think%20COPD%20differently/PDE4%20inhibition%20in%20COPD.aspx>

FYI - Click to download article on PDE4 inhibition

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707810/>

**Bronchodilator combinations**

- ^ Moderate-to-severe
- ^ Beta-agonist and anticholinergic -  
greater response than either one,  
alone
  - ◆ formoterol and tiotropium -  
persistent symptoms
  - ◆ albuterol and ipratropium -  
intermittent symptoms

FYI - Click to download GOLD COPD guidelines 2010

<http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html>

**Corticosteroids**

- ^ Oral corticosteroids; e.g., prednisone  
- exacerbations
- ^ Inhaled corticosteroids (ICS)
  - ◆ severe-to-very severe COPD
  - ◆ not recommended as monotherapy

FYI - Click to download GOLD COPD pocket guide

<http://www.goldcopd.org/guidelines-pocket-guide-to-copd-diagnosis.html>

**Combined steroid and LABA**

- ▲ Indication - in addition to tiotropium for severe and very severe COPD
- ▲ Benefits
  - ◆ decreased exacerbations - cost effective
  - ◆ improved symptoms and HRQoL
  - ◆ decreased mortality
- ▲ Preparations
  - ◆ formoterol/budesonide (Symbicort)
  - ◆ salmeterol/fluticasone (Advair)

**Mucolytic agents**

- ▲ Oral n-acetylcysteine (COPD):
  - ◆ may improve pulmonary function
  - ◆ may reduce risk of hospitalization
  - ◆ effects may be due to antioxidant activity
- ▲ No evidence supporting nebulized n-acetylcysteine
- ▲ No evidence supporting nebulized Pulmozyme for COPD

**Mucolytic agents**

- ▲ Oral mucolytics available outside the U.S.A. (not FDA-approved)
  - ◆ carbocysteine
  - ◆ ambroxol

**Antibiotics**

- ▲ Indication - evidence of bacterial infection
- ▲ Recurrent infections indicate prolonged courses
- ▲ Not for routine prophylaxis

**Medications and rehabilitation**

- ▲ Instruction and monitoring medication self-administration is integral to rehabilitation.
- ▲ Selection of specific agent(s) should be based on:
  - ◆ patient response
  - ◆ cost
  - ◆ patient's ability to self-administer

FYI - Click to download GOLD therapy-by-stage  
<http://img.medscape.com/fullsize/migrated/editorial/journalcme/2008/17618/fromer.fig2.gif>

**Medications and rehabilitation**

- ▲ Adherence can be problematic - it does affect outcomes
- ▲ Non-adherence may be due to:
  - ◆ memory impairment
  - ◆ cost
  - ◆ perceived difficulty (too much stuff)
  - ◆ perception on ineffectiveness

**Medications and rehabilitation**

- △ Encouraging adherence
  - ◆ memory aids
  - ◆ cheaper drugs
  - ◆ assistance with payment
  - ◆ patient education on expectations
  - ◆ drugs with lesser frequency
  - ◆ follow-up

**Oxygen Therapy****Indications for O2 therapy**

- △ Manage hypoxemia at rest and during exercise.
- △ Increase exercise capacity for patients without hypoxemia during high-intensity training.

**Benefits of O2 therapy**

- △ Prolongs survival for patients with severe COPD and resting hypoxemia
  - ◆ long term oxygen therapy (LTOT) -  $\geq 15$  hours/day

**Benefits of O2 therapy**

- △ Increases endurance during high-intensity exercise
  - ◆ permits greater exercise intensity
  - ◆ decreases respiratory rate
  - ◆ decreases dynamic hyperinflation
  - ◆ decreases leg fatigue
- △ Prevents nocturnal desaturation

**Nocturnal O2 therapy**

- △ COPD - may desaturate at night and require more O2
- △ COPD + OSA (overlap syndrome)
  - ◆ polysomnography needed for suspected patients
  - ◆ managed by OSA guidelines

**Adverse effects**

- △ O<sub>2</sub> tissue toxicity - not at low FIO<sub>2</sub>
- △ Oxygen-induced hypoventilation
  - ◆ very rare
  - ◆ during exacerbations
  - ◆ high FIO<sub>2</sub>
- △ Accidents
  - ◆ smoking with O<sub>2</sub>
  - ◆ cylinder mishaps
  - ◆ liquid O<sub>2</sub> spills

Click to see extreme smoker

[http://tobacco.mededu.miami.edu/tobacco/studyPlan/slides\\_az/slide-j.jpg](http://tobacco.mededu.miami.edu/tobacco/studyPlan/slides_az/slide-j.jpg)

**Physiological criteria for home O<sub>2</sub>**

- △ Continuous O<sub>2</sub>
  - ◆ PaO<sub>2</sub> ≤ 55 mm Hg or SaO<sub>2</sub> ≤ 88%  
OR
  - ◆ PaO<sub>2</sub> = 56-59 mm Hg or SaO<sub>2</sub> = 89%  
AND
    - dependent edema from CHF OR
    - pulmonary hypertension
  - ◆ Desaturation within first minute of six minute walk test (6 MWT) - suggested by study

**Physiological criteria for home O<sub>2</sub>**

- △ Nocturnal O<sub>2</sub> only - PaO<sub>2</sub> ≤ 55 mm Hg or SaO<sub>2</sub> ≤ 88% during sleep OR drop in SaO<sub>2</sub> > 5%
- △ Exercise O<sub>2</sub> only - PaO<sub>2</sub> ≤ 55 mm Hg or SaO<sub>2</sub> ≤ 88%

**Prescription for LTOT**

- △ Prescribe O<sub>2</sub> for PaO<sub>2</sub> ≥ 60 mm Hg or SaO<sub>2</sub> ≥ 90%
- △ Add 1 L/min additional during exercise and for rest after exercise OR titrate O<sub>2</sub> flow for PaO<sub>2</sub> ≥ 60 mm Hg or SaO<sub>2</sub> ≥ 90%
- △ If the hypoxemia identified during exacerbation, recheck ABGs 30-90D to determine need for LTOT

**Home O<sub>2</sub> systems**

- △ Compressed gas cylinder systems
  - ◆ require no electrical power
  - ◆ limited duration
  - ◆ limited portability
- △ Liquid O<sub>2</sub> systems
  - ◆ require no electrical power
  - ◆ long duration (860:1)

Click to see various liquid O<sub>2</sub> systems

<http://www.portableoxygenconcentrators.com/page9.html>

**Home O<sub>2</sub> systems**

- △ Compressed gas cylinder systems
  - ◆ require no electrical power
  - ◆ limited duration
  - ◆ limited portability
- △ Liquid O<sub>2</sub> systems
  - ◆ require no electrical power
  - ◆ long duration (860:1)
- △ Concentrators
  - ◆ require electrical power
  - ◆ portable units available

Click to see various O<sub>2</sub> concentrators

<http://www.oxygenconcentratorstore.com/>

**Home O2 devices**

- ▲ Standard nasal cannula "nose-hose"
- ▲ Reservoir nasal cannula
  - ◆ bolus of O2 during inspiration
  - ◆ conserves O2 supply
- ▲ Pulsed flow cannula
  - ◆ O2 flow during inspiration, only
  - ◆ conserves O2 supply
  - ◆ increased comfort (less drying)

Click to see a reservoir device

<http://ccn.aacnjournals.org/content/22/4/41/F2.expansion>

Click to see a pulsed flow device

[http://73.bp.blogspot.com/\\_q6mZ\\_sruvqTE/BU\\_7\\_SaI/AAAAAAAAACA/6GKqHC0J\\_gM/s1600/Electrical+Pulse+Demand+Oxygen+System.jpg](http://73.bp.blogspot.com/_q6mZ_sruvqTE/BU_7_SaI/AAAAAAAAACA/6GKqHC0J_gM/s1600/Electrical+Pulse+Demand+Oxygen+System.jpg)

**Home O2 devices**

- ▲ Transtracheal oxygen therapy (TTOT)
  - ◆ aesthetically desirable - psychosocial benefits
  - ◆ permits more active lifestyle
  - ◆ lesser flow rate - conserves O2
  - ◆ can combine with pulse delivery device

Click to see TTOT device

<http://health.ucsd.edu/specialties/pulmonary/procedures/PublishingImages/TTOT1.jpg>

Click for more information on TTOT device. View animated illustration and clinician page.

<http://www.tto2.com/>

**Home O2 devices**

- ▲ Transtracheal device (TTOT)
  - ◆ aesthetically desirable - psychosocial benefits
  - ◆ permits more active lifestyle
  - ◆ lesser flow rate - conserves O2
  - ◆ can combine with pulse delivery device
  - ◆ less discomfort - increases adherence
  - ◆ treats OSA
  - ◆ requires special knowledge and skills
  - ◆ requires minor surgery

FYI - Click to print article on TTOT

<http://www.rtmagazine.com/news/16499-transtracheal-oxygen-therapy-the-best-kept-secret-in-medicine>

**Patient education on O2 therapy**

- ▲ Topics
  - ◆ devices
  - ◆ device usage - how & when
  - ◆ troubleshooting
  - ◆ contacts for devices & supplies
- ▲ Competency-based evaluations
  - ◆ knowledge - examinations
  - ◆ procedures - performance checklists

FYI - Click for website on patient's perspective of home O2 (a patient resource)

<http://www.portableoxygen.org/>

**Patient adherence to LTOT**

- ▲ LTOT adherence is 45 - 70%
- ▲ Reasons for non-adherence
  - ◆ hassle & expense of supplies
  - ◆ limitation of mobility
  - ◆ nasal irritation
  - ◆ embarrassment
  - ◆ fear of dependence

**Patient adherence to LTOT**

- ▲ LTOT adherence is 45 - 70%
- ▲ Reasons for non-adherence
  - ◆ hassle & expense of supplies
  - ◆ limitation of mobility
  - ◆ nasal irritation
  - ◆ embarrassment
  - ◆ fear of dependence
  - ◆ inadequate communication
  - ◆ perception of no benefit
  - ◆ desire for freedom to smoke

**Methods to improve adherence**

- ^ Instruction on need & benefits
- ^ Regular follow-up
- ^ Family instruction & social support
- ^ Portable delivery systems - small and light

**Methods to improve adherence**

- ^ Instruction on need & benefits
- ^ Regular follow-up
- ^ Family instruction & social support
- ^ Portable delivery systems - small and light
- ^ Concentrators - avoid problems with refills and deliveries
- ^ TTOT - decreases embarrassment
- ^ Smoking cessation, fire safety

Click for video on smoking with O2 (1.2 min)  
<http://www.youtube.com/watch?v=D7QpSfvyOek>

**Travel with O2**

- ^ Important enabler for rehab patients.
- ^ Commercial aircraft pressurized to 8000 ft.
- ^ O2 required for patients with:
  - ◆ sea level RA PaO<sub>2</sub> < 73
  - ◆ FEV<sub>1</sub> < 1.5 (maybe)
- ^ Altitude simulation test may be needed

FYI - Click for article on altitude simulation test  
<http://chestjournal.chestpubs.org/content/133/4/1002.full.pdf+html>

**Travel with O2**

- ^ Check with airline before flight
- ^ Airline security must be notified
- ^ Liquid oxygen (LOX) systems may NOT be carried on aircraft (store with luggage)

FYI - Click for article for patients traveling with O2  
[www.accpstorage.org/newOrganization/patients/TravelingwithOxygen.pdf](http://www.accpstorage.org/newOrganization/patients/TravelingwithOxygen.pdf)

**Travel with O2**

- ^ Check with airline before flight
- ^ Airline security must be notified
- ^ LOX systems may NOT be carried on aircraft (store with luggage)
- ^ Portable O2 concentrator is best; but requires approval by airline
- ^ CPAP devices require external power source
- ^ Some airlines provide O2 source for a fee

**Pulse oximetry**

- ^ Oximeters are available at Walmart
- ^ Two-edge sword - patient requires thorough instruction
- ^ Purposes:
  - ◆ home O2 monitoring
  - ◆ sleep apnea monitoring
  - ◆ monitoring patients with congenital heart disease
  - ◆ high altitude travel & activities

**Pulse oximetry**

- ^ Insurers recognize oximetry to:
  - ◆ determine appropriate home oxygen liter flow
  - ◆ monitor patients on home ventilators
  - ◆ adjust for change in the patient's condition
  - ◆ wean patients from home oxygen.

FYI - click for patient information on pulse oximetry  
<http://www.copd-alert.com/OximetryPG.pdf>

**Inspiratory Muscle  
Training**

**Concepts**

- ^ Weakness - reduced force that is not changed by rest
- ^ Fatigue - reduced force that changes with rest (occurs in normals)
- ^ Strength - maximum force generated ( $PI_{MAX}$ )

FYI - click for ATS respiratory muscle testing statement  
<http://ajrccm.atsjournals.org/cgi/content/full/166/4/518>

**Concepts**

- ^ Weakness - reduced force that is not changed by rest
- ^ Fatigue - reduced force that changes with rest (occurs in normal patients)
- ^ Strength - maximum force generated ( $PI_{MAX}$ )
- ^ Endurance
  - ◆ PI sustainable over time - inspiratory muscles
  - ◆ maximum voluntary ventilation (MVV) - inspiratory and expiratory muscles

**Rationale for IMT**

- ^ COPD patients typically have weak inspiratory muscles
- ^ Exercises intend to increase the strength and/or endurance of ventilatory muscles, thereby:
  - ◆ decreasing breathlessness
  - ◆ increasing ventilatory muscle efficiency
  - ◆ increasing exercise capacity - effective, even for normal individuals

**Conditions that may benefit**

- ^ Asthma
- ^ Heart failure rehabilitation
- ^ Bariatric surgery - preoperatively
- ^ Thoracic restrictive disease
- ^ Failure to wean from mechanical ventilation

**Conditions that benefit**

- ^ Selected COPD patients
  - ◆ moderate-to-severe; but, not end-stage
  - ◆ exertional dyspnea
  - ◆ decreased  $PI_{MAX}$  (>80 cm H<sub>2</sub>O excludes weakness)
  - ◆ motivated - will adhere to training

**Exercise techniques**

- ^ Types
  - ◆ sustained hyperpnea
  - ◆ inspiratory resistance
- ^ Intended goals
  - ◆ strength - high workload, few repetitions
  - ◆ endurance - moderate workload, many repetitions

**Exercise devices**

- ^ Threshold resistors (preferred)
- ^ Flow restrictors - patient can reduce load by decreasing flow
- ^ Incentive spirometers - ineffective

Click to see Respironics Threshold IMT™ device

<http://thresholdimt.respironics.eu/>

Click to see Micromedical MRNA™ device

<http://www.respiratorymuscles.com/aboutus/respiratoryprofile.htm>

Click to see Powerbreathe™ device

<http://www.powerbreathe.com/>

**Exercise prescription**

- ^ Frequency  $\geq 5$  days/week
- ^ Duration 30 min/day, continuous or divided into two sessions
- ^ Intensity > 30% initial  $PI_{MAX}$  (adjusted as tolerated)


**Measured outcomes**

- ^  $PI_{MAX}$
- ^ Dyspnea; e.g., by BDI/TDI indexes
- ^ Health status; e.g., by SGRQ
- ^ Exercise performance; e.g., by 6 MWD

**General Exercise  
Training**

**Physical reconditioning exercises**

- △ Rationale - to reverse the effects of inactivity that are due to dyspnea
- △ The most important factor in pulmonary rehabilitation for symptomatic respiratory disease
- △ Beneficial to almost everyone, except:
  - ◆ pure cardiac pump failure
  - ◆ degenerative neuromuscular diseases

**Chronic disease cascade****Benefits of reconditioning exercises**

- △ Increased  $VO_{2MAX}$
- △ Increased muscle strength and endurance
- △ Improved muscle coordination
- △ Increased muscle mass, decreased adipose tissue
- △ Improved sense of well-being
- △ Improved chance of survival (possibly)

**Regimen benefits**

- △ Aerobic training - increases endurance
  - ◆ lower extremities
  - ◆ upper extremities
- △ Strength training - increases muscle strength and muscle mass
  - ◆ lower extremities
  - ◆ upper extremities

**Regimen benefits**

- △ Aerobic training
  - ◆ high-intensity exercise - exercise at levels near individual peak capacity produces greatest physiological benefit; however,
  - ◆ both low and high-intensity exercises produce clinical benefits

**Exercises**

- △ Leg exercises
  - ◆ walking
  - ◆ treadmill walking
  - ◆ cycle ergometer
  - ◆ stair climbing
- △ Arm exercises
  - ◆ arm ergometer
  - ◆ weights
  - ◆ elastic resistance bands

**Exercise prescription**^ **Developed by:**

- ◆ MD, and/or
- ◆ Physical therapist (PT) - essential for targeting muscle groups for strength training and/or
- ◆ Exercise physiologist and/or
- ◆ RCP

^ **Implemented by:**

- ◆ PT and/or
- ◆ RCP and/or
- ◆ Rehab RN

**Exercise implementation**

- ^ **Recommended frequency and duration - 3 times/week; 8-12 weeks??**
- ^ **Increase intensity as tolerated**
- ^ **Monitoring**
  - ◆ pulse oximetry - SpO2 and heart rate
  - ◆ respiratory rate
  - ◆ reported dyspnea

Click to see exercise prescription table  
<http://www.pulmonaryrehab.com.au/index.asp?page=98>

**Maintenance program**

- ^ **Training effects can be lost after one month without exercise**
- ^ **Maintenance programs**
  - ◆ Home exercise program
  - ◆ Monthly outpatient exercise program

FYI - Click to see examples of training programs  
<http://www.pulmonaryrehab.com.au/index.asp?page=97>

**Adjunctive therapeutics**

- ^ **Supplemental oxygen**
- ^ **Noninvasive positive pressure ventilation (NPPV)**
  - ◆ better than O2? (small study)
  - ◆ nocturnal - effects carry over to day time
  - ◆ during exercise
    - uncomfortable
    - unwieldy

**Adjunctive therapeutics**

- ^ **Heliox**
  - ◆ low density gas decreases WOB
  - ◆ collective evidence does not support effectiveness with PR
- ^ **Neuromuscular electric stimulation (NMES) - low voltage stimulation of motor nerves**
  - ◆ increases recovery of muscle strength
  - ◆ more research needed

FYI - Click for article on NMES and COPD  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071998/pdf/clin-66-03-401.pdf>

**Rehabilitation for  
Miscellaneous Conditions**

**Conditions that may benefit**

- △ **Obstructive conditions**
  - ◆ asthma
  - ◆ cystic fibrosis
  - ◆ diffuse bronchiectasis
- △ **Restrictive conditions**
  - ◆ pulmonary fibrosis
  - ◆ sarcoidosis
  - ◆ ARDS survivors
  - ◆ collagen vascular diseases
  - ◆ thoracic restriction; e.g., kyphoscoliosis

**Conditions that may benefit**

- △ **Neuromuscular disease; e.g., Guillain-Barre syndrome**
- △ **Pulmonary vascular disease - pulmonary hypertension**
- △ **Lung cancer**
- △ **Recovery from thoracic surgery:**
  - ◆ transplants
  - ◆ lung volume reduction surgery (LVRS)

**Non-COPD programs**

- △ **Same goals as for COPD**
  - ◆ improve HRQoL
  - ◆ increase exercise capacity
- △ **Different program content**
  - ◆ instruction on different medications
  - ◆ disease-specific physical and occupational therapy
  - ◆ exercises focusing on different muscle groups

**Asthma program**

- △ **Patient groups**
  - ◆ adults, including pregnant women
  - ◆ children (K+)
  - ◆ parents
- △ **Instructional delivery**
  - ◆ certified asthma educator
  - ◆ computer-based programs
  - ◆ asthma camps

FYI - click for National Asthma Education Certification Board website  
<http://www.naecb.org/>

**Asthma program**

- △ **Educational topics**
  - ◆ asthma pathophysiology
  - ◆ asthma triggers
  - ◆ early warning signs
  - ◆ PEF monitoring
  - ◆ medications & self-administration techniques

**Asthma program**

- △ **Exercise**
  - ◆ warm up - important
  - ◆ self-monitor for exercise-induced bronchospasm
  - ◆ submaximal exercises
    - aerobics
    - walking
    - yoga

FYI - click for Asthma Education Center with online videos on asthma topics  
<http://asthmaeducationcenter.net/>

**Cystic fibrosis program**

- ^ Education topics
  - ◆ lung clearance techniques
  - ◆ medications & self-administration techniques
  - ◆ nutrition
  - ◆ infection control

**Cystic fibrosis program**

- ^ Exercise precautions
  - ◆ may require supplemental O<sub>2</sub>
  - ◆ avoid hot environments - sweating
  - ◆ maintain hydration with electrolytes
  - ◆ maintain nutrition

**Restrictive lung disease**

- ^ Education topics
  - ◆ disease pathophysiology
  - ◆ energy conservation
  - ◆ oxygen therapy
  - ◆ relaxation techniques
  - ◆ medications
  - ◆ nutrition
  - ◆ breathing retraining - pursed lip breathing????

**Restrictive lung disease**

- ^ Exercise training
  - ◆ may not tolerate
  - ◆ may not benefit - desaturate with exercise
  - ◆ supplemental oxygen may be required
  - ◆ NPPV may be required

**Neuromuscular disease**

- ^ Education topics
  - ◆ pathophysiology
  - ◆ medications
  - ◆ cough assist; e.g., mechanical in/ex sufflator
  - ◆ NPPV devices & procedures

**Neuromuscular disease**

- ^ Exercise training - condition specific
  - ◆ strength and endurance training
  - ◆ respiratory muscle training
- ^ Exercise precautions
  - ◆ some patients do not benefit; e.g., spinal/bulbar muscular atrophy
  - ◆ avoid IMT in patients with hypercapnea

**Special  
Issues**

**Issues**

- ▲ Outcome assessment
- ▲ Patient adherence
- ▲ Ethical & end-of-life issues
- ▲ Social & recreational support

**Outcome assessment**

- ▲ Components
  - ◆ Clinical
  - ◆ Behavioral
  - ◆ Health
  - ◆ Service

Click to see and/or download outcome matrix  
<http://www.upcra.org/images/111507-handout03.doc>

FYI - click for AACVPR statement on outcome assessment

[http://journals.lww.com/jcr/journal/Fulltext/2009/11000/Patient\\_and\\_Program\\_Outcome\\_Assessment\\_In.11.aspx](http://journals.lww.com/jcr/journal/Fulltext/2009/11000/Patient_and_Program_Outcome_Assessment_In.11.aspx)

**Outcome assessment**

- ▲ Clinical component
  - ◆ overall management
    - ▶ BODE index
    - ▶ ADL assessment
  - ◆ exercise testing and training
    - ▶ maximal & submaximal exercise test
    - ▶ heart rate
    - ▶ SpO2

Click to see and/or download BODE index scoring  
<http://www.pulmonaryrehab.com.au/pdfs/BodeIndexForCOPD.pdf>

**Outcome assessment**

- ▲ Clinical component
  - ◆ strength & flexibility training
  - ◆ nutrition & weight management
    - ▶ body mass index
    - ▶ nutritional biochemical markers
  - ◆ psychosocial management
    - ▶ mood
    - ▶ cognitive function
  - ◆ smoking cessation

**Outcome assessment**

- ▲ Behavioral component
  - ◆ overall management
    - ▶ knowledge and self-care actions
    - ▶ medication adherence
    - ▶ supplemental O2 adherence
  - ◆ exercise testing & training
    - ▶ exercise compliance
    - ▶ energy expenditure

**Outcome assessment**

- ^ Behavioral component
  - ◆ breathing retraining - effectiveness
  - ◆ bronchial hygiene - mucus clearance
  - ◆ nutrition & weight management
    - diet & exercise adherence
    - physical activity logs

**Outcome assessment**

- ^ Behavioral component
  - ◆ breathing retraining - effectiveness
  - ◆ bronchial hygiene - mucus clearance
  - ◆ nutrition & weight management
    - diet & exercise adherence
    - physical activity logs
  - ◆ psychosocial management
    - coping mechanisms
    - social support network
  - ◆ smoking cessation - stage of change

**Outcome assessment**

- ^ Health component
  - ◆ healthcare utilization
  - ◆ adverse events during sessions
  - ◆ HRQoL
- ^ Service component
  - ◆ patient satisfaction
  - ◆ performance measures
    - cost per patient
    - program cost
    - completion rate

**Patient adherence**

- ^ Extent of problem
  - ◆ 50% of all patients adhere to treatment recommendations
  - ◆ 37% of patients with lung disease adhere to treatments
- ^ Components of problem
  - ◆ medications
  - ◆ oxygen therapy
  - ◆ exercise
  - ◆ NPPV

**Patient adherence**

- ^ Reasons for non-adherence
  - ◆ forgetting
  - ◆ inadequate communications from physicians/other caregivers
  - ◆ medication side effects
  - ◆ perception that interventions do not work
  - ◆ cost of medications
  - ◆ inconvenience

**Patient adherence**

- ^ Measures to improve adherence
  - ◆ reminders - telephone, e-mail
  - ◆ enhanced physician communications
  - ◆ set realistic goals for exercise
  - ◆ establish rewards for desirable behaviors
  - ◆ focus on positive outcomes
  - ◆ telemonitoring - there's an 'app'

FYI - click for Smartphone article  
<http://www.hindawi.com/journals/ijta/2008/753064/>

**Ethical & end-of-life issues**

- △ After acute exacerbations of COPD
  - ◆ median survival = 2 years
  - ◆ readmission within 6 mo. = 50%
- △ Pulmonary rehabilitation patients are receptive to end-of-life planning, assisted by rehabilitation educators

**Ethical & end-of-life issues**

- △ Patients want information; e.g.:
  - ◆ nature of disease process
  - ◆ role and limitations of treatments
  - ◆ prognosis for survival and QoL
  - ◆ planning for future care, including exacerbations

**Ethical & end-of-life issues**

- △ Discussions on advance planning
  - ◆ are improved by ambulatory setting
  - ◆ are improved by skilled communicators
  - ◆ should incorporate a team-based approach (including lawyer)

**Social & recreational support**

- △ Purposes:
  - ◆ decrease anxiety
  - ◆ decrease loneliness, sense of isolation
  - ◆ improve self-image
  - ◆ extend benefits of PR program
- △ Patient support group; e.g., Better Breathers Club is an instrumental medium.

FYI - click for article on patients' experiences with PR  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2942866/pdf/tids32-1272.pdf>

**Social & recreational support**

- △ Support for BBC
  - ◆ home care, durable medical equipment (DME) companies
  - ◆ American Lung Association
  - ◆ hospital - social services department
- △ Location for meetings
  - ◆ must be accessible
  - ◆ must accommodate special needs

FYI - click for article on starting and running a BBC  
<http://www.breathingbetterlivingwell.com/basics/pulmonarygroup.php>

**Social & recreational support**

- △ Publicity for meetings, especially the first one, is necessary
- △ Monthly meeting days/times - midweek, midday
- △ Meetings provide:
  - ◆ name tags & introductions
  - ◆ speakers - stimulating
  - ◆ beverages, snacks

**Social & recreational support**

- ^ Organization - patient board of directors
- ^ Funding
  - ◆ no dues
  - ◆ fundraising activities
- ^ Social events - aim for fun:
  - ◆ birthdays
  - ◆ holidays
  - ◆ picnics
  - ◆ group trips

**Social & recreational support**

- ^ Encourage wellness & physical activities during, or as the events, e.g.:
  - ◆ walks
  - ◆ swimming outings
  - ◆ dancing
  - ◆ aerobics
  - ◆ cooking classes
- ^ Encourage social networking; e.g., Facebook, etc.

**Summary & Review**

- ^ Pharmacotherapy - lesser frequency gets greater adherence
  - ◆ immunizations
  - ◆ bronchodilators
  - ◆ corticosteroids
  - ◆ combined medications
  - ◆ mucolytics

**Summary & Review**

- ^ Oxygen therapy
  - ◆ indications
  - ◆ benefits of LTOT - prolonged survival & increased exercise endurance
  - ◆ physiologic criteria
  - ◆ prescription
  - ◆ home O2 systems & devices - competency-based education
  - ◆ travel with O2

**Summary & Review**

- ^ Respiratory muscle training
  - ◆ conditions that benefit - selected COPD patients
  - ◆ strength & endurance
  - ◆ exercise prescription
  - ◆ exercise techniques
  - ◆ exercise devices
  - ◆ measured outcomes

**Summary & Review**

- ^ General exercise training
  - ◆ rationale - reverse effects of inactivity
  - ◆ benefits - increased exercise capacity
  - ◆ regimens - aerobics, strength training
  - ◆ exercises - legs and upper extremities
  - ◆ prescription
  - ◆ implementation
  - ◆ adjuncts - NPPV, O2, heliox, NMES

**Summary & Review**

## ^PR for non-COPD

- ◆ conditions that may benefit
- ◆ goals - same as for COPD
- ◆ program content - specific for disease and patient
- ◆ programs for:
  - ▶ asthma
  - ▶ cystic fibrosis
  - ▶ restrictive lung diseases
  - ▶ neuromuscular diseases

**Summary & Review**

## ^Special issues

- ◆ outcome assessment - matrix
- ◆ patient adherence, including improvement methods.
- ◆ ethical and end-of-life issues - advance planning
- ◆ social & recreational support - better breathers

**References**

- ^Hodgkin JE, Celli BR, Connors GL. Pulmonary rehabilitation: Guidelines to success 2009; Chs. 7, 9, 10, 11, 12, 20, 21, 23, 24, 25. Mosby, Inc.; St Louis.
- ^Ries AL. ACCP/AACVPR evidence-based guidelines for pulmonary rehabilitation. Round 3: another step forward. *J Cardiopulm Rehabil Prev.* 2007 Jul-Aug;27(4):233-6.
- ^Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2010 Dec 31;6:13-22.
- ^Kang SW. Pulmonary rehabilitation in patients with neuromuscular disease. *Yonsei Med J.* 2006 Jun 20;47(2):207-14.

**References**

- ^Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B; Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. *Respir Res.* 2010 Oct 5;11:135.
- ^Malmberg LP, Ryttilä P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. *Int J Chron Obstruct Pulmon Dis.* 2010 Aug 9;5:257-62.
- ^Kliber A, Lynd LD, Sin DD. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. *Respir Res.* 2010 May 11;11:56.

**References**

- ^Miravittles M, Llor C, Molina J, Naberan K, Cots JM, Ros F. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. *Int J Chron Obstruct Pulmon Dis.* 2010 Feb 18;5:11-9.
- ^Laforest L, Denis F, Van Ganse E, Ritleng C, Saussier C, Passante N, Devouassoux G, Chatté G, Freymond N, Pacheco Y. Correlates of adherence to respiratory drugs in COPD patients. *Prim Care Respir J.* 2010 Jun;19(2):148-54.
- ^Puhan M. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2011 May 11.
- ^Tzeng AC, Bach JR. Prevention of pulmonary morbidity for patients with neuromuscular disease. *Chest.* 2000 Nov;118(5):1390-6.

**References**

- ^Butler RJ, Davis TK, Johnson WG, Gardner HH. Effects of nonadherence with prescription drugs among older adults. *Am J Manag Care.* 2011 Feb;17(2):153-60.
- ^Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. *Respir Med.* 2011 Mar;105(3):435-41.
- ^Sanford M. Roflumilast: in chronic obstructive pulmonary disease. *Drugs.* 2010; 20:1615-27.
- ^Ninot G, Moullec G, Picot MC, Jaussent A, Hayot M, Desplan M, Brun JF, Mercier J, Prefaut C. Cost-saving effect of supervised exercise associated to COPD self-management education program. *Respir Med.* 2010 Oct 28.

**References**

- ▲ Borghi-Silva A, Mendes RG, Toledo AC, Malosá Sampaio LM, da Silva TP, Kunikushita LN, Dutra de Souza HC, Salvini TF, Costa D. Adjuncts to physical training of patients with severe COPD: oxygen or noninvasive ventilation? *Respir Care*. 2010 Jul;55(7):885-94.
- ▲ Voduc N, Tessier C, Sabri E, Fergusson D, Lavallee L, Aaron SD. Effects of oxygen on exercise duration in chronic obstructive pulmonary disease patients before and after pulmonary rehabilitation. *Can Respir J*. 2010 Jan-Feb;17(1):e14-9.
- ▲ Corner E, Garrod R. Does the addition of non-invasive ventilation during pulmonary rehabilitation in patients with chronic obstructive pulmonary disease augment patient outcome in exercise tolerance? A literature review. *Physiother Res Int*. 2010 Mar;15(1):5-15.

**References**

- ▲ Borel JC, Wuyam B, Chouri-Pontarollo N, Deschaux C, Levy P, Pépin JL. During exercise non-invasive ventilation in chronic restrictive respiratory failure. *Respir Med*. 2008 May;102(5):711-9.
- ▲ Janaudis-Ferreira T, Hill K, Goldstein R, Wadell K, Brooks D. Arm exercise training in patients with chronic obstructive pulmonary disease: a systematic review. *J Cardiopulm Rehabil Prev*. 2009 Sep-Oct;29(5):277-83.
- ▲ Meek PM, Lareau SC. Critical outcomes in pulmonary rehabilitation: assessment and evaluation of dyspnea and fatigue. *J Rehabil Res Dev*. 2003 Sep-Oct;40(5 Suppl 2):13-24.
- ▲ Yaeger ES, Goodman S, Hoddes E, Christopher KL. Oxygen therapy using pulse and continuous flow with a transtracheal catheter and a nasal cannula. *Chest*. 1994 Sep;106(2):954-60.

**References**

- ▲ Peno-Green L, Verrill D, Vitcenda M, Macintyre N, Graham H; American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR). Patient and program outcome assessment in pulmonary rehabilitation: an AACVPR statement. *J Cardiopulm Rehabil Prev*. 2009 Nov-Dec;29(6):402-10.
- ▲ Soffer M, Tashkin DP, Shapiro BJ, Littner M, Harvey E, Farr S. Conservation of oxygen supply using a reservoir nasal cannula in hypoxemic patients at rest and during exercise. *Chest*. 1985 Nov;88(5):663-8.
- ▲ Sériès F, Forge JL, Lampron N, Cormier Y. Transtracheal air in the treatment of obstructive sleep apnoea hypopnoea syndrome. *Thorax*. 2000 Jan;55(1):86-7.
- ▲ Ingram G, Munro N. *Br J Gen Pract*. 2005 Jul;55(516):501-2. The use (or otherwise) of pulse in general practice.

**References**

- ▲ Singh S, Harrison S, Houchen L, Wagg K. Exercise assessment and training in pulmonary rehabilitation for patients with COPD. *Eur J Phys Rehabil Med*. 2011 Sep;47(3):483-97.
- ▲ Bosnak-Guclu M, Arıkan H, Savcı S, Inal-Ince D, Tulumen E, Aytemir K, Tokgözoğlu L. Effects of inspiratory muscle training in patients with heart failure. *Respir Med*. 2011 Nov;105(11):1671-81. Epub 2011 May 31.
- ▲ Barbalho-Moulim MC, Miguel GP, Forti EM, Campos Fdo A, Costa D. Effects of preoperative inspiratory muscle training in obese women undergoing open bariatric surgery: respiratory muscle strength, lung volumes, and diaphragmatic excursion. *Clinics (Sao Paulo)*. 2011;66(10):1721-7.

**References**

- ▲ Martin AD, et al. Inspiratory muscle strength training improves weaning outcome in failure to wean patients: a randomized trial. *Crit Care*. 2011;15(2):R84.
- ▲ Gosselink R, De Vos J, van den Heuvel SP, Segers J, Decramer M, Kwakkel G. Impact of inspiratory muscle training in patients with COPD: what is the evidence? *Eur Respir J*. 2011 Feb;37(2):416-25.
- ▲ ATS/ERS Statement on Respiratory Muscle Testing. *Am. J. Respir. Crit. Care Med*. 166: 518-624.
- ▲ Hunt T, Williams MT, Frith P, Schembri D. Heliox, dyspnoea and exercise in COPD. *Eur Respir Rev*. 2010 Mar 1;19(115):30-8.
- ▲ Probst VS, Kovelis D, Hernandez NA, Camillo CA, Cavalheri V, Pitta F. Effects of 2 exercise training programs on physical activity in daily life in patients with COPD. *Respir Care*. 2011 Nov;56(11):1709-97.

**References**

- ▲ Scorsone D, et al. Does a low-density gas mixture or oxygen supplementation improve exercise training in COPD? *Chest*. 2010 Nov;138(5):1133-9.
- ▲ Allan PF, Thomas KV, Ward MR, Harris AD, Naworol GA, Ward JA. Feasibility study of noninvasive ventilation with helium-oxygen gas flow for chronic obstructive pulmonary disease during exercise. *Respir Care*. 2009 Sep;54(9):1175-82.
- ▲ Johnson JE, Gavin DJ, Adams-Dramiga S. Effects of training with heliox and noninvasive positive pressure ventilation on exercise ability in patients with severe COPD. *Chest*. 2002 Aug;122(2):464-72.
- ▲ Garcia-Talavera I, et al. Time to desaturation less than one minute predicts the need for long-term home oxygen therapy. *Respir Care*. 2011 Nov;56(11):1812-7.

**References**

- ^Katsenos S, Constantopoulos S. Long-Term Oxygen Therapy in COPD: Factors Affecting and Ways of Improving Patient Compliance. *Pulmonary Medicine*;2011: 8 p.
- ^Markovitz GH, Cooper CB. Rehabilitation in non-COPD: mechanisms of exercise limitation and pulmonary rehabilitation for patients with pulmonary fibrosis/restrictive lung disease. *Chron Respir Dis*. 2010;7(1):47-60. Epub 2009 Oct 30.
- ^Shannon VR. Role of pulmonary rehabilitation in the management of patients with lung cancer. *Curr Opin Pulm Med*. 2010 Jul;16(4):334-9.
- ^Salhi B, Troosters T, Behaegel M, Joos G, Derom E. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. *Chest*. 2010;137(2):273-9.

**References**

- ^Koessler W, Wanke T, Winkler G, Nader A, Toifl K, Kurz H, Zwick H. 2 Years' experience with inspiratory muscle training in patients with neuromuscular disorders. *Chest*. 2001 Sep;120(3):765-9.
- ^Melillo EM, Sethi JM, Mohsenin V. Guillain-Barré syndrome: rehabilitation outcome and recent developments. *Yale J Biol Med*. 1998 Sep-Oct;71(5):383-9.